Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Pancreatic Cancer Vaccine in metastatic pancreatic cancer
NCT03563144Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2018
- Primary completion
- Dec 2019
- Modality
- Adenoviral Vectors, DNA Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, haNK, aldoxorubicin, ETBX-011, ETBX-021, sponsored by ImmunityBio, Inc.. Planned start Aug 2018; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicepthaNKaldoxorubicinETBX-011ETBX-021
Beyond the preview
Go deeper on NCT03563144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563144.